Profil
Greg Mann is currently working as the Media & Investor Relations Contact at Nkarta, Inc. He previously worked as the Director-Investor Relations at Abgenix, Inc., Executive Director-IR & Corporate Communications at FibroGen, Inc., and Vice President-Investor Relations at Kite Pharma, Inc.
Postes actifs de Greg Mann
| Sociétés | Poste | Début |
|---|---|---|
| NKARTA, INC. | Investor Relations Contact | 01/02/2020 |
Anciens postes connus de Greg Mann
| Sociétés | Poste | Fin |
|---|---|---|
Abgenix, Inc.
 Abgenix, Inc. BiotechnologyHealth Technology Abgenix, Inc. developed therapeutic products. It focused on the discovery, development and manufacturing of therapeutic antibodies. The firm's antibody development platform included manufacturing fully human antibody product candidates to a variety of disease targets. The company was founded by R. Scott Greer in 1996 and was headquartered in Fremont, CA. | Investor Relations Contact | 01/01/2006 |
| KITE PHARMA INC | Investor Relations Contact | - |
| FIBROGEN, INC. | Investor Relations Contact | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| FIBROGEN, INC. | Health Technology |
| NKARTA, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Abgenix, Inc.
Abgenix, Inc. BiotechnologyHealth Technology Abgenix, Inc. developed therapeutic products. It focused on the discovery, development and manufacturing of therapeutic antibodies. The firm's antibody development platform included manufacturing fully human antibody product candidates to a variety of disease targets. The company was founded by R. Scott Greer in 1996 and was headquartered in Fremont, CA. | Health Technology |
Kite Pharma, Inc.
 Kite Pharma, Inc. BiotechnologyHealth Technology Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA. | Health Technology |
